Green Valley Pharma, the Shanghai drugmaker that scored a stunning approval to market an Alzheimer’s drug in China two years ago, has shuttered a Phase III trial that would’ve paved its way to the FDA.
Impacted by “multiple negative factors” and after “careful evaluation,” Green Valley Pharmaceutical has decided to terminate a global phase 3 trial early for its seaweed-derived Alzheimer’s drug oligomannate, or GV-971, according to a statement (Chinese) posted Friday.
A Phase III study of a seaweed-derived Alzheimer’s drug, conditionally approved in China in November 2019, has been halted, five trial sites have confirmed to Endpoints News.